Munich Re's €6.6 Billion Target Faces a Quality Audit It Didn't Ask For

Munich Re closed the week at €591.00, up 1.0%, as a friendlier European insurance sector and a better-than-feared claims load combined to lift the stock. Yet the gain sits alongside a more awkward question for shareholders: how much of the group's earnings power rests on underwriting, and how much on buying back its own shares?

Berenberg put that question on the table on Friday, reaffirming a "Hold" rating with a €565 price target. The broker's argument cuts against the grain of the headline numbers. In its view, the quality of earnings is deteriorating, and earnings per share are leaning ever more heavily on buybacks. For investors, that reframes the debate: the point is no longer simply what Munich Re earned, but whether the operating business can carry those earnings without a capital-markets assist. A higher EPS figure on its own would not answer the objection.

A solid base, but a different test

Thursday's release offers plenty of substance. Third-quarter 2026 group profit came in at €1.74 billion, down from €2 billion a year earlier. Major-loss claims for the quarter totalled €646 million — below the expected 18% of net insurance revenue, even with natural catastrophe losses running higher, as dpa-AFX reported. That undershoot was a concrete driver of the positive share-price reaction, according to the news agency.

Across the first nine months, profit reached €5.67 billion, against €5.18 billion in the same period of 2025, on insurance revenue of €46.6 billion. Munich Re also lifted its 2026 profit target to €6.6 billion from €6.3 billion, with the Handelsblatt reporting on Thursday that the group expects more profitable business in property-casualty and in specialty reinsurance over the full year.

What matters for the valuation now is which of those figures can be extrapolated — and at what quality.

The combined ratio as the real yardstick

The operating loss experience is the sharper test. Major-loss claims ran at 14.9% of insurance revenue over the nine months, well shy of the 18% that had been anticipated. Munich Re simultaneously improved its expected combined ratio for property-casualty reinsurance to below 80%, and for Global Specialty Insurance it now guides to below 90%.

Those targets support the bullish reading of the business. They do not, on their own, settle how resilient the result would prove under a harsher claims environment. That is precisely why the operating ratios deserve more weight than a standalone look at per-share earnings. Berenberg's scepticism and the company's upgraded expectations are addressing different layers of the same investment case.

Buybacks: support act or smokescreen?

The bear case is not that repurchases are inherently bad for the stock. The risk lies in what they come to mean for the overall picture. If EPS is increasingly propped up by buybacks, its trajectory can convey more strength than the underlying group result warrants.

The programme is running steadily. Between 30 October and 9 November inclusive, Munich Re bought back 115,000 of its own shares. Since the programme began, purchases have totalled 3,304,311 shares, according to the notice published on Tuesday. Those figures prove no operating weakness by themselves — but they turn Berenberg's point into a live item on the checklist. The negative scenario would pair fading support from benign claims with a growing buyback contribution to per-share earnings; in that combination, even a met profit target could lose some of its persuasive force.

What would settle the argument

Should claims experience continue to validate the improved expectations, the optimistic operating reading holds. The high profit would no longer be explainable as a favourable snapshot, and underwriting could act as a counterweight to doubts about earnings quality. Buybacks would then supplement per-share development rather than dominate the investor's field of view — a stronger rebuttal to Berenberg than any further lift in the metric without operating confirmation.

If that support fades, the quality question gains weight. The decisive distinction for shareholders is between a result carried by the insurance business and a figure shaped increasingly by capital measures.

Two dates will sharpen the picture. CFO Andrew Buchanan is confirmed to appear at the J.P. Morgan European Financials Conference in London on 19 November, where comments on the durability of earnings could matter for the valuation — though no new guidance has been promised. Then comes the announced "Outlook 2027" on 10 December. Until then, operating confirmation of the upgraded targets should be the deciding factor. It could soften Berenberg's doubts. Without it, the headline profit alone will not answer the question of how long it can last.